| Phase 18 trials |
|
Phase 1
|
NCT05981365 |
Apr → Oct 2023 |
sickle cell disease |
Pfizer |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03114540 |
Mar 2017 → Feb 2018 |
— |
Pfizer |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03051711 |
Dec 2016 → Dec 2017 |
— |
Global Blood Therapeutics |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT03161015 |
Nov 2016 → May 2017 |
impaired renal function disease |
Global Blood Therapeutics |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02567695 |
Sep 2015 → Jun 2016 |
sickle cell disease |
Global Blood Therapeutics |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02567682 |
Sep 2015 → May 2016 |
sickle cell disease |
Global Blood Therapeutics |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02497924 |
Jun 2015 → Jul 2016 |
sickle cell disease |
Global Blood Therapeutics |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02285088 |
Dec 2014 → Mar 2017 |
sickle cell disease |
Global Blood Therapeutics |
Completed
|
No outcome recorded
|
| Phase 1/21 trial |
|
Phase 1/2
|
NCT04335721 |
Mar 2021 → Oct 2024 |
sickle cell disease |
University of Illinois at Chicago |
Terminated
|
No outcome recorded
|
| Phase 29 trials |
|
Phase 2
|
NCT06023199 |
Oct 2023 → Sep 2025 |
sickle cell disease |
Inova Health Care Services |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT05199766 |
Mar 2023 → Mar 2024 |
sickle cell disease |
Assistance Publique - Hôpitaux de Paris |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT05289570 |
May 2022 → Jun 2023 |
acute lung injury |
Duke University |
Terminated
|
No outcome recorded
Stop: Business |
|
Phase 2
|
NCT05018728 |
Mar 2022 → Oct 2024 |
sickle cell disease |
Emory University |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT04247594 |
Jan 2020 → Jun 2021 |
sickle cell disease |
Pfizer |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT02989168 |
Nov 2016 → Oct 2017 |
idiopathic pulmonary fibrosis, polycythemia due to hypoxia |
Global Blood Therapeutics |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT03041909 |
Aug 2016 → Jun 2017 |
sickle cell disease |
Global Blood Therapeutics |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02850406 |
Jul 2016 → Oct 2023 |
sickle cell disease |
Pfizer |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT02846324 |
Jun 2016 → Sep 2017 |
idiopathic pulmonary fibrosis, polycythemia due to hypoxia |
Global Blood Therapeutics |
Completed
|
No outcome recorded
|
| Phase 35 trials · 1 met primary · 1 missed |
|
Phase 3
|
NCT05228834 |
Jun → Sep 2022 |
sickle cell disease |
Pfizer |
Terminated
|
No outcome recorded
|
|
Phase 3
|
NCT05561140 |
May 2022 → Jun 2024 |
sickle cell disease, ulcer of lower limbs |
Pfizer |
Terminated
|
Missed primary
|
|
Phase 3
|
NCT04218084 |
Nov 2020 → Jan 2024 |
sickle cell disease |
Pfizer |
Terminated
|
Met primary
|
|
Phase 3
|
NCT04188509 |
Nov 2019 → Nov 2024 |
sickle cell disease |
Pfizer |
Terminated
|
No outcome recorded
|
|
Phase 3
|
NCT03573882 |
Jun 2018 → Nov 2024 |
sickle cell disease |
Pfizer |
Terminated
|
No outcome recorded
|
| Phase 43 trials |
|
Phase 4
|
NCT05228821 |
Aug 2023 |
sickle cell disease |
Pfizer |
Withdrawn
|
No outcome recorded
Stop: Business |
|
Phase 4
|
NCT04400487 |
Dec 2020 → Sep 2022 |
sickle cell disease |
Pfizer |
Completed
|
No outcome recorded
|
|
Phase 4
|
NCT04581356 |
Sep 2020 → Oct 2021 |
sickle cell disease |
Elizabeth Yang, MD, PhD |
Completed
|
No outcome recorded
|
| Phase not stated1 trial |
| — |
NCT04724421 |
— |
sickle cell disease |
Pfizer |
No longer available
|
No outcome recorded
|
| Comparator or background therapy2 trials |
|
Phase 3
|
NCT03036813 Comparator |
Dec 2016 → Oct 2019 |
sickle cell disease |
Pfizer |
Completed
|
No outcome recorded
|
| — |
NCT03943615 Background |
— |
sickle cell disease |
Pfizer |
No longer available
|
No outcome recorded
|